Global Dry Eye Disease Market Report 2022: Increasing Emergence of Novel Treatments Presents Opportunities
20 déc. 2022 08h33 HE
|
Research and Markets
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Dry Eye Disease Market By product, By distribution channel & By region-Forecast Analysis 2022-2028" report has been added to ...
Ophthalmic Drugs Market to Develop at CAGR of 6.83% during Forecast Period: TMR Study
16 nov. 2022 13h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - In 2021, the value of the ophthalmic drugs market stood at US$ 26.46 Bn. Analysis of...
Global Dry Eye Treatment Devices Market Report 2022: High Incidence & Prevalence of Dry Eye Diseases Boosting Sector
08 nov. 2022 06h48 HE
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast,...
Vaccentis strengthens leadership with appointment of Mario Stark as Chief Sales and Marketing Officer
08 sept. 2022 02h00 HE
|
Vaccentis AG
Life science executive with experience in ophthalmology, branding, marketing and financingWill lead sales and marketing of medicines for dry eye and autoimmune diseases Zurich, Switzerland,...
Outlook on the OTC Artificial Tears Global Market to 2027 - Development of Novel Approach Presents Opportunities
16 août 2022 05h03 HE
|
Research and Markets
Dublin, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The "Global OTC Artificial Tears Market (2022-2027) by Product, Container Type, Formulation, Application, Distribution Channel, Geography, Competitive...
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
21 juil. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular...
Xequel Bio Announces Positive Results from Phase 1b Study of iNexin™, a Novel aCT1 Ophthalmic Solution
14 juil. 2022 09h00 HE
|
Xequel Bio, Inc.
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet...
Vaccentis stärkt Management durch Berufung von Martin Munte zum CEO
12 juil. 2022 02h00 HE
|
Vaccentis AG
Pharmamanager mit langjährige Führungserfahrung bei Amgen, AstraZeneca und RocheWeitere Verstärkung des Managements nach Ernennung dreier neuer Mitglieder im Verwaltungsrat Zurich, Schweiz, 12....
Vaccentis appoints Martin Munte as CEO and strengthens Board
12 juil. 2022 02h00 HE
|
Vaccentis AG
Martin Munte has extensive leadership experience at Amgen, AstraZeneca and RocheStrengthening management after appointment of three new Board members Zurich, Switzerland, July 12, 2022 -...
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
24 mai 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...